99 related articles for article (PubMed ID: 2865088)
1. Changes in blood pressure, fluid volumes and glomerular filtration rate during long-term treatment with prizidilol, an antihypertensive drug with combined vasodilatator and beta-adrenoceptor blocking actions.
Andersen GS; Hartling OJ; Hein HO; Leth A
Dan Med Bull; 1985 Oct; 32(5):280-3. PubMed ID: 2865088
[TBL] [Abstract][Full Text] [Related]
2. Dose-response relationship of prizidilol hydrochloride (SK&F 92657): a comparison between acute and chronic effects in patients with essential hypertension.
Pedrinelli R; Abdel-Haq B; Magagna A; Leto di Priolo S; Simonini N; Salvetti A
Int J Clin Pharmacol Res; 1984; 4(2):155-63. PubMed ID: 6147320
[TBL] [Abstract][Full Text] [Related]
3. Antihypertensive effect of prizidilol.
Jounela AJ; Honkala M; Huikuri H
Ann Clin Res; 1984; 16(3):176-80. PubMed ID: 6383185
[TBL] [Abstract][Full Text] [Related]
4. Prizidilol, a combined vasodilatory and beta-adrenoceptor blocking drug, in primary hypertension. A long-term efficacy, tolerance and pharmacokinetic study.
Karlberg BE; Larsson R; Ohman KP; Norlander B; Wirsen A; Hed J; Lundh BL; Flock A
Eur J Clin Pharmacol; 1983; 25(2):179-86. PubMed ID: 6138257
[TBL] [Abstract][Full Text] [Related]
5. Prizidilol in essential hypertension: long-term effects on plasma volume, extracellular fluid volume, and central hemodynamics at rest and during exercise.
Lund-Johansen P; Omvik P
J Cardiovasc Pharmacol; 1982; 4(6):1012-7. PubMed ID: 6185765
[TBL] [Abstract][Full Text] [Related]
6. Acute effects of prizidilol on blood pressure, heart rate, catecholamines, renin and aldosterone in essential hypertension.
Bianchetti MG; Boehringer K; Weidmann P; Link L; Schiffl H; Ziegler WH
Eur J Clin Pharmacol; 1982 Oct; 23(4):289-96. PubMed ID: 6129141
[TBL] [Abstract][Full Text] [Related]
7. Prizidilol (SK & F 92657), a new vasodilator with beta-blocking properties in the treatment of essential hypertension.
Lüscher T; Havelka J; Greminger P; Tuma J; Täuber M; Siegenthaler W; Vetter W
Eur J Clin Pharmacol; 1982; 23(5):411-5. PubMed ID: 6129980
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular response to mental stress: dynamic and isometric exercise in hypertensive patients treated with prizidilol hydrochloride (SK&F 92657).
Costa FV; Borghi C; Boschi S; Ambrosioni E
Int J Clin Pharmacol Res; 1984; 4(5):373-9. PubMed ID: 6151553
[TBL] [Abstract][Full Text] [Related]
9. Cadralazine, a new vasodilator, in addition to a beta-blocker for long-term treatment of hypertension.
Salvadeo A; Villa G; Segagni S; Piazza V; Picardi L; Romano M; Parini J
Arzneimittelforschung; 1985; 35(3):623-5. PubMed ID: 2859865
[TBL] [Abstract][Full Text] [Related]
10. Blood pressure, plasma volume, extracellular volume and glomerular filtration rate during treatment with labetalol in essential hypertension.
Rasmussen S; Nielsen PE
Postgrad Med J; 1980; 56 Suppl 2():33-6. PubMed ID: 7433340
[TBL] [Abstract][Full Text] [Related]
11. Beta-adrenoceptor blockade and vasodilatation in essential hypertension. Hemodynamic studies at rest and during exposure to stress.
Eggertsen R
Acta Med Scand Suppl; 1984; 689():1-46. PubMed ID: 6151343
[TBL] [Abstract][Full Text] [Related]
12. Antihypertensive effect of prizidilol.
Andrén L; Hansson L; Svensson A
J Cardiovasc Pharmacol; 1983; 5(5):898-900. PubMed ID: 6195483
[TBL] [Abstract][Full Text] [Related]
13. Effects of guanabenz on sodium and water homeostasis.
Braden G; Alvis R; Walker BR; Cox M
J Clin Hypertens; 1987 Dec; 3(4):397-404. PubMed ID: 3453382
[TBL] [Abstract][Full Text] [Related]
14. Prizidilol, an antihypertensive with precapillary vasodilator and beta-adrenoceptor blocking actions, in primary hypertension.
Larsson R; Karlberg BE; Norlander B; Wirsén A
Clin Pharmacol Ther; 1981 May; 29(5):588-93. PubMed ID: 6111409
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial.
Sramek JJ; Leibowitz MT; Weinstein SP; Rowe ED; Mendel CM; Levy B; McMahon FG; Mullican WS; Toth PD; Cutler NR
J Hum Hypertens; 2002 Jan; 16(1):13-9. PubMed ID: 11840225
[TBL] [Abstract][Full Text] [Related]
16. Randomly allocated study of the effects of standard therapy versus ACE inhibition on micro-albuminuria in essential hypertension.
Ruilope LM; Lahera V; Alcázar JM; Praga M; Campo C; Rodicio JL
J Hypertens Suppl; 1994 Jul; 12(4):S59-63. PubMed ID: 7965276
[TBL] [Abstract][Full Text] [Related]
17. Effects of timolol on blood pressure, systemic hemodynamics, plasma renin activity, and glomerular filtration rate in patients with essential hypertension.
Valvo E; Gammaro L; Tessitore N; Fabris A; Ortalda V; Bedogna V; Maschio G
Int J Clin Pharmacol Ther Toxicol; 1984 Mar; 22(3):156-61. PubMed ID: 6370874
[TBL] [Abstract][Full Text] [Related]
18. Acute effects of combined vasodilation and beta-adrenoceptor blockade with prizidilol on renal function.
Boehringer K; Weidmann P; Link L; Bianchetti MG; Schiffl H; Reubi FC
Br J Clin Pharmacol; 1983 Feb; 15(2):181-8. PubMed ID: 6133543
[TBL] [Abstract][Full Text] [Related]
19. [Long-term treatment with captopril in arterial hypertension complicated by renal failure].
Durand D; Ader JL; Emal V; Bories P; Girolami JP; Suc JM
Arch Mal Coeur Vaiss; 1982 Jun; 75 Spec No():151-6. PubMed ID: 6126168
[TBL] [Abstract][Full Text] [Related]
20. Antihypertensive efficacy of a new long acting hydralazine like vasodilator, ISF 2469 in combination with a betablocker and a diuretic.
van Brummelen P; Bühler FR; Kiowski W; Bolli P; Bertel O
Int J Clin Pharmacol Biopharm; 1979 Oct; 17(10):380-5. PubMed ID: 40887
[No Abstract] [Full Text] [Related]
[Next] [New Search]
